Pluristem Therapeutics Inc. (NASDAQ:PSTI) Major Shareholder Clover Wolf Capital – Limited Purchases 49,000 Shares

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited acquired 49,000 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were acquired at an average price of $7.36 per share, with a total value of $360,640.00. Following the completion of the purchase, the insider now owns 2,601,311 shares in the company, valued at approximately $19,145,648.96. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Wednesday, June 10th, Clover Wolf Capital – Limited acquired 25,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $6.91 per share, with a total value of $172,750.00.
  • On Monday, June 8th, Clover Wolf Capital – Limited acquired 178,717 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.36 per share, with a total value of $1,315,357.12.
  • On Thursday, June 4th, Clover Wolf Capital – Limited acquired 7,610 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.86 per share, with a total value of $59,814.60.
  • On Tuesday, June 2nd, Clover Wolf Capital – Limited acquired 117,489 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.57 per share, with a total value of $889,391.73.
  • On Sunday, May 31st, Clover Wolf Capital – Limited acquired 1,797 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.95 per share, with a total value of $14,286.15.
  • On Wednesday, May 27th, Clover Wolf Capital – Limited acquired 90,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $8.14 per share, with a total value of $732,600.00.

Shares of NASDAQ PSTI opened at $8.84 on Wednesday. The firm has a market cap of $219.17 million, a PE ratio of -2.68 and a beta of 2.60. The firm has a fifty day moving average of $8.28 and a 200 day moving average of $5.75. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.47 and a current ratio of 2.47. Pluristem Therapeutics Inc. has a one year low of $2.82 and a one year high of $13.29.

Several analysts have commented on the stock. Dawson James restated a “buy” rating on shares of Pluristem Therapeutics in a research note on Wednesday, April 15th. HC Wainwright reaffirmed a “buy” rating and set a $15.50 target price on shares of Pluristem Therapeutics in a report on Thursday, May 14th. Zacks Investment Research lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Jefferies Financial Group initiated coverage on shares of Pluristem Therapeutics in a report on Friday, June 19th. They set a “buy” rating and a $12.00 target price for the company. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 target price on shares of Pluristem Therapeutics in a report on Friday, May 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $12.20.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 5.9% in the 1st quarter. Jane Street Group LLC now owns 71,294 shares of the biotechnology company’s stock worth $262,000 after acquiring an additional 3,945 shares in the last quarter. ETF Managers Group LLC increased its holdings in Pluristem Therapeutics by 9.8% in the 1st quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 5,764 shares in the last quarter. Levin Capital Strategies L.P. purchased a new stake in Pluristem Therapeutics in the 1st quarter worth $37,000. Finally, Renaissance Technologies LLC increased its holdings in Pluristem Therapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock worth $1,077,000 after acquiring an additional 87,188 shares in the last quarter. 7.82% of the stock is owned by institutional investors.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also: How does the Beige Book influence monetary policy?

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.